<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869294</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYY-PAC1</org_study_id>
    <nct_id>NCT03869294</nct_id>
  </id_info>
  <brief_title>GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients</brief_title>
  <official_title>Gemcitabine Plus S-1 as the First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved
      objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with
      locally advanced and metastatic pancreatic cancer (PC). However, limited data of GS regimen
      exist on the efficacy and safety in the treatment of Chinese patients with advanced PC. To
      assess the efficacy and safety of gemcitabine plus S-1 (GS regimen) as the first-line
      chemotherapy in Chinese patients with advanced PC, we designed this prospective study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2014-01-01 to 2017-12-31</time_frame>
    <description>the time from the beginning of chemotherapy to the date of disease progression or death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2014-01-01 to 2017-12-31</time_frame>
    <description>the time from the beginning of chemotherapy to the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2014-01-01 to 2017-12-31</time_frame>
    <description>the percentage of patients with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2014-01-01 to 2017-12-31</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <arm_group>
    <arm_group_label>LAPC or MPC patients with GS first-line chemotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS</intervention_name>
    <description>Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer</description>
    <arm_group_label>LAPC or MPC patients with GS first-line chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All advanced pancreatic cancer patients are diagnosed by histology to have pancreatic
        adenocarcinoma after a biopsy and received first-line GS chemotherapy at the Cancer
        Biotherapy Center of the First Affiliated Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Histologically confirmed pancreatic adenocarcinoma 2.Locally advanced or metastatic
             PC 3.Chemotherapy-naïve 4.ECOG performance status of 0 or 1 5. An adequate bone
             marrow, liver function and kidney function

        Exclusion Criteria:

          -  1.Age ≥80 years 2.Brain metastasis 3.With other malignancies 4.Chronic diarrhea,
             cardiac disease, pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang, MD</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

